Catheter Precision (VTAK) Current Deferred Revenue (2017 - 2026)
Catheter Precision (VTAK) reported Current Deferred Revenue of $126000.0 for Q1 2026, down 92.95% on a QoQ basis from $1.8 million in Q2 2021.
Catheter Precision (VTAK) has 6 years of Current Deferred Revenue data on file, last reported at $126000.0 in Q1 2026.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $126000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $126000.0 (changed N/A YoY) and the FY2020 annual result came in at $2.5 million, down 24.24% from the prior year.
- Current Deferred Revenue eased to $126000.0 in Q1 2026 per VTAK's latest filing, from $1.8 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $126000.0 in Q1 2026 and bottomed at $126000.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Catheter Precision | 2.01 Mn | 1.20 Mn | 390,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 126,000.00 |
| Jun 30, 2021 | 1.79 Mn |
| Mar 31, 2021 | 1.78 Mn |
| Dec 31, 2020 | 2.50 Mn |
| Sep 30, 2020 | 1.73 Mn |
| Jun 30, 2020 | 1.86 Mn |
| Mar 31, 2020 | 1.96 Mn |
| Dec 31, 2019 | 3.30 Mn |
| Sep 30, 2019 | 1.92 Mn |
| Jun 30, 2019 | 2.04 Mn |
| Mar 31, 2019 | 1.95 Mn |
| Dec 31, 2018 | 1.72 Mn |
| Sep 30, 2018 | 1.75 Mn |
| Dec 31, 2017 | 1.71 Mn |